Khosla Ventures’ Post

Transcript

You know, the work that people or companies like Al Nilam and Ionas actually did as we look at delivering nucleic acid to cells, how to actually do that, you know, how to manufacture it, all of that stuff. I think CRISPR CAS 9 happened to come at a point where there was such a data, a level of data that was out there and sophistication that allowed us then to move it forward extremely rapidly and clearly, you know, for a struggle already approved in that space, I think, which is almost unprecedented for novel modality.